173019-83-5

Usage

Uses

Used in Pharmaceutical Industry:
Benzene, 1-(3-bromo-1-propynyl)-4-(trifluoromethyl)is used as a reactant for the preparation of propargyl bromide precursors to allenylcyclopropanols. These precursors are essential in the synthesis of various pharmaceutical compounds, particularly those with potential therapeutic applications. The unique structure of Benzene, 1-(3-bromo-1-propynyl)-4-(trifluoromethyl)- allows for the creation of complex molecules with specific biological activities, making it a valuable component in the development of new drugs.
Used in Chemical Synthesis:
In the field of chemical synthesis, Benzene, 1-(3-bromo-1-propynyl)-4-(trifluoromethyl)serves as a versatile building block for the creation of a wide range of organic compounds. Its reactivity and functional groups make it suitable for use in various synthetic pathways, leading to the production of compounds with diverse applications, such as agrochemicals, dyes, and advanced materials.
Used in Research and Development:
Due to its unique structure and reactivity, Benzene, 1-(3-bromo-1-propynyl)-4-(trifluoromethyl)is also utilized in research and development for the exploration of new chemical reactions and the discovery of novel compounds with potential applications in various industries. Its use in research can lead to the development of new synthetic methods, improved drug candidates, and innovative materials with enhanced properties.

Upstream product

• 455-13-0 4-Iodobenzotrifluoride 
• 173546-21-9 3-(4-trifluoromethylphenyl)prop-2-yn-1-ol 

Downstream Products

• 1037510-10-3 phenyl 4,6-O-benzylidene-2-O-[3-(4-trifluoromethylphenyl)-prop-2-ynyl]-3-O-benzyl-1-thio-α-D-mannopyranoside 
• 1037510-09-0 3-O-[3-(4-trifluoromethylphenyl)-prop-2-ynyl]-1,2:5,6-di-O-isopropylidene-α-D-glucofuranose 
• 1620300-88-0 C₁₈H₁₃F₃O₃ 
• 1188541-05-0 1,3-dipropyl-8-{1-[3-(4-trifluoromethylphenyl)prop-2-ynyl]-1H-pyrazol-4-yl}-3,7-dihydropurine-2,6-dione 
• 1188541-70-9 1-propyl-8-{1-[3-(4-trifluoromethylphenyl)prop-2-ynyl]-1H-pyrazol-4-yl}-3,7-dihydropurine-2,6-dione 
• 1188541-01-6 3-ethyl-1-propyl-8-{1-[3-(4-trifluoromethylphenyl)prop-2-ynyl]-1H-pyrazol-4-yl}-3,7-dihydropurine-2,6-dione 

Relevant academic research and scientific papers

Copper(I)-Catalyzed Intramolecular Cyclization of o-Propargyloxy Diketopiperazines to Access Diverse Diazabicyclic and Spiro-Diketopiperazinochromanes

In this report, two distinctive intramolecular cyclizations of o-propargyloxy diketopiperazines (achieved from a one-pot Ugi post-transformation) is achieved via a copper(I)-catalyzed intramolecular reaction of azomethine ylide and alkyne moiety. The presence of internal alkyne in the starting materials directed the reaction towards through [3+2]-cycloaddition, while terminal alkyne led to a spirocyclization reaction between azomethine ylide and terminal unsaturated C?C bond. This method offering an opportunity for the synthesis of challenging Diazabicyclics and Spiro-Diketopiperazinochromanes in high yields with exclusive diastereoselectivity. (Figure presented.).

Synthesis of Carbolines via Palladium/Carboxylic Acid Joint Catalysis

The combination of a Pd(0) complex with benzoic acid converts propargylic tryptamines to the corresponding tetrahydro-β-carbolines. The method uses unprotected indoles and affords the desired products with ample functional group tolerance. Detailed modeling studies reveal a close synergy between the organic and metal catalysts, which enables sequential alkyne isomerization, indole C-H activation, and eventual C-C reductive elimination to afford the target heterocycles.

Design and synthesis of novel xanthine derivatives as potent and selective A2B adenosine receptor antagonists for the treatment of chronic inflammatory airway diseases

Adenosine induces bronchial hyperresponsiveness and inflammation in asthmatics through activation of A2B adenosine receptor (A2BAdoR). Selective antagonists have been shown to attenuate airway reactivity and improve inflammatory cond

A one-pot-three-step route to triazolotriazepinoindazolones from oxazolino-2H-indazoles

A one-pot-three-step method has been developed for the conversion of oxazolino-2H-indazoles into triazolotriazepinoindazolones with three points of diversity. Step one of this process involves a propargyl bromide-initiated ring opening of the oxazolino-2H-indazole (available by the Davis-Beirut reaction) to give an N1-(propargyl)-N2-(2-bromoethyl)-disubstituted indazolone, which then undergoes -CH2Br → -CH2N 3 displacement (step two) followed by an uncatalyzed intramolecular azide-alkyne 1,3-dipolar cycloaddition (step three) to form the target heterocycle. Employing 7-bromooxazolino-2H-indazole allows for further diversification through, for example, palladium-catalyzed coupling chemistry, as reported here.

Isotopic labelling studies for a gold-catalysed skeletal rearrangement of alkynyl aziridines

Isotopic labelling studies were performed to probe a proposed 1,2-aryl shift in the gold-catalysed cycloisomerisation of alkynyl aziridines into 2,4-disubstituted pyrroles. Two isotopomers of the expected skeletal rearrangement product were identified usi

Gold(I)-catalyzed enantioselective ring expansion of allenylcyclopropanols

(Chemical Equation Presented) The asymmetric gold(I)-catalyzed ring expansion of 1-allenylcyclopropanols is described. The method provides synthetically valuable cyclobutanones with a vinyl-substituted quaternary stereogenic center in high enantioselectivities and yields. The method shows a broad substrate scope, tolerating protected alcohols and amines, alkenes, unsaturated esters, and acetals. The reaction is easily adjustable to large-scale synthesis, leading to product formation without significant loss of selectivity or yield with only 0.5 mol% catalyst loading.

Tricyclic triazolic compounds

The present invention relates to new tricyclic triazolic compounds having a high affinity for sigma-1 receptor as well as to the process for the preparation thereof, to composition comprising them and to their use as medicaments according to compounds of

Intramolecular azide-Alkyne for the fast assembly of structurally diverse, tricyclic 1,2,3-triazoles

The synthesis of novel tricyclic 1,2,3-triazoles starting from cyclic epoxides via the sequential azidolysis, propargylation and 1,3-dipolar cycloaddition is described. Derivatization by N-arylation reaction and the synthesis of enantiomerically pure comp

Novel 5-(3-aryl-2-propynyl)-5-(arylsulfonyl)thiazolidine-2,4-diones as antihyperglycemic agents

Novel 5-(3-aryl-2-propynyl)-5-(arylsulfonyl)thiazolidine-2,4-diones and 5-(3-aryl-2-propynyl)5-(arylsulfanyl)thiazolidine-2,4-diones were prepared and evaluated as oral antihyperglycemic agents in the obese, insulin resistant db/db mouse model at 100 mg/kg and, if the analogue had sufficient potency, 20 mg/kg. The sulfonylthiazolidinediones, 2, were more potent than the corresponding sulfanylthiazolidinedione congeners, 1. With regard to substituent effects on the 3-propynyl phenyl ring (Ar') of 2, 4-halogen substitution generally resulted in the more potent analogues. Substituent effects on the phenylsulfonyl moiety (Ar) of 2 were less clear, although para-halogen substitution on Ar generally was preferable. 2-Pyridinesulfonyl derivatives (Ar = 2-pyridine in 2) also had good potency. Several compounds from series 2 were effective at lowering glucose and insulin in the obese, insulin resistant ob/ob mouse at the 50 mg/kg oral dose. Compound 20 significantly improved the glucose tolerance of obese, insulin resistant Zucker rats at the 20 mg/kg dose level and had no effect on plasma glucose or on glucose tolerance in normal rats fasted for 18 h at the 100 mg/kg level.